WHAT IS CLAIMED IS:

1. A conjugate of two or more monoclonal antibodies, wherein the conjugate comprises a monoclonal antibody that does not comprise an Fc region.

2. The conjugate of claim 1, wherein no monoclonal antibody comprised in the conjugate comprises an Fc region.

3. The conjugate of claim 1, wherein the conjugate comprises a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form.

4. The conjugate of claim 3, wherein the conjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.

5. The conjugate of claim 3, wherein the conjugate comprises an anti-Her2 monoclonal antibody.

6. The conjugate of claim 1, wherein the conjugate comprises a monoclonal antibody that asserts substantially no anti-neoplastic activity in an unconjugated form.

7. The conjugate of claim 1, wherein the antibodies are conjugated via hypercrosslinking.

8. The conjugate of claim 1, wherein the conjugate comprises a monoclonal antibody that is an IgG monomer.

9. The conjugate of claim 1, wherein the IgG is a mammalian IgG.

10. The conjugate of claim 1, wherein the conjugate is a homoconjugate.

11. A method of making a conjugate of two or more monoclonal antibodies, wherein the conjugate comprises a monoclonal antibody that does not comprise an Fc region, comprising:

obtaining a first monoclonal antibody that does not comprise an Fc region;

obtaining a second monoclonal antibody; and

conjugating the first monoclonal antibody to the second monoclonal antibody.

12. The method of claim 11, wherein no monoclonal antibody comprised in the conjugate comprises an Fc region.

13. The method of claim 11, wherein the first monoclonal antibody is a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form.

14. The method of claim 11, wherein the second monoclonal antibody is a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form.

15. The method of claim 11, wherein both the first monoclonal antibody and the second monoclonal antibody are a monoclonal antibodies that assert anti-neoplastic activity in a conjugated form.

16. The method of claim 14, wherein the second monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.

17. The method of claim 14, wherein the second monoclonal antibody is an anti-Her2 monoclonal antibody.

18. The method of claim 11, wherein the first monoclonal antibody is a monoclonal antibody that asserts substantially no anti-neoplastic activity in an unconjugated form.

19. The method of claim 11, wherein the second monoclonal antibody is a monoclonal antibody that asserts substantially no anti-neoplastic activity in an unconjugated form.

20. The method of claim 11, wherein both the first monoclonal antibody and the second monoclonal antibody are monoclonal antibodies that assert substantially no anti-neoplastic activity in an unconjugated form.

21. The method of claim 11, wherein the antibodies are conjugated via hypercrosslinking.

22. The method of claim 11, wherein the conjugate comprises a monoclonal antibody that is an IgG monomer.

23. The method of claim 11, wherein the conjugate comprises a mammalian monoclonal antibody.

24. The method of claim 11, wherein the conjugate is a homoconjugate.

25. The method of claim 11, further consisting of:

obtaining a third monoclonal antibody; and

conjugating the third monoclonal antibody to the conjugate.

26. A method of signaling an anti-neoplastic activity comprising:

obtaining a conjugate of two or more monoclonal antibodies, wherein the conjugate comprises a monoclonal antibody that does not comprise an Fc region and wherein the conjugate comprises a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form; and

contacting a neoplastic cell with the conjugate.

27. The method of claim 26, wherein the conjugate comprises a monoclonal antibody that signals growth arrest.

28. The method of claim 27, wherein the conjugate comprises a tumor reactive monoclonal antibody.

29. The method of claim 28, wherein the conjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.

30. A method of detecting the presence of a neoplastic disease comprising:

contacting a biological sample suspected of comprising a neoplastic antigen with a conjugate comprising a monoclonal antibody; and

screening for an immunological reaction.

31. The method of claim 30, wherein the first monoclonal antibody is a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form.

32. The method of claim 30, wherein the second monoclonal antibody is a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form.

33. The method of claim 30, wherein both the first monoclonal antibody and the second monoclonal antibody are monoclonal antibodies that assert anti-neoplastic activity in a conjugated form.

34. The method of claim 30, wherein the second monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.

35. The method of claim 30, wherein the second monoclonal antibody is an anti-Her2 monoclonal antibody.

36. The method of claim 30, wherein the first monoclonal antibody is a monoclonal antibody that asserts substantially no anti-neoplastic activity in an unconjugated form.

37. The method of claim 30, wherein the second monoclonal antibody is a monoclonal antibody that asserts substantially no anti-neoplastic activity in an unconjugated form.

38. The method of claim 30, wherein both the first monoclonal antibody and the second monoclonal antibody are monoclonal antibodies that assert substantially no anti-neoplastic activity in an unconjugated form.

39. The method of claim 30, wherein the antibodies are conjugated via hypercrosslinking.

40. The method of claim 30, wherein the conjugate comprises a monoclonal antibody that is an IgG.

41. The method of claim 30, wherein the conjugate comprises a mammalian antibody.

42. The method of claim 30, wherein the conjugate is a homo-conjugate.

43. A pharmaceutical composition comprising a conjugate comprising a monoclonal antibody and a pharmaceutically acceptable carrier.

44. The pharmaceutical composition of claim 43, wherein no monoclonal antibody comprised in the conjugate comprises an Fc region.

45. The pharmaceutical composition of claim 43, wherein the conjugate comprises a monoclonal antibody that asserts anti-neoplastic activity in a conjugated form.

46. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti-αHer2 monoclonal antibody.

47. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti-αHer2 monoclonal antibody.

48. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is a monoclonal antibody that asserts substantially no anti-neoplastic activity in an unconjugated form.

49. The pharmaceutical composition of claim 43, wherein the antibodies are conjugated via hypercrosslinking.

50. The pharmaceutical composition of claim 43, wherein the conjugate comprises a monoclonal antibody that is an IgG monomer.

51. The pharmaceutical composition of claim 43, wherein the conjugate comprises a mammalian monoclonal antibody.

52. The pharmaceutical composition of claim 43, wherein the conjugate is a homoconjugate.